High RBM3 expression has been associated with improved survival in a number of malignancies, e.g. breast cancer, malignant melanoma, uroepithelial cancer, ovarian cancer, colorectal cancer, gastroesophageal cancer, and testicular cancer [16–22]. This evidence concerns the gene RBM3 and ovarian carcinoma.